Wedmont Private Capital raised its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 17.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,843 shares of the company’s stock after purchasing an additional 2,779 shares during the quarter. Wedmont Private Capital’s holdings in Eli Lilly and Company were worth $22,039,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Intelligence Driven Advisers LLC raised its stake in Eli Lilly and Company by 9.7% during the 3rd quarter. Intelligence Driven Advisers LLC now owns 725 shares of the company’s stock valued at $839,000 after purchasing an additional 64 shares during the period. Journey Retirement Planning & Investment Management LLC lifted its holdings in Eli Lilly and Company by 13.9% in the 3rd quarter. Journey Retirement Planning & Investment Management LLC now owns 797 shares of the company’s stock worth $923,000 after purchasing an additional 97 shares in the last quarter. Central Bank & Trust Co. boosted its stake in Eli Lilly and Company by 1.0% in the 3rd quarter. Central Bank & Trust Co. now owns 2,219 shares of the company’s stock worth $2,568,000 after purchasing an additional 21 shares during the period. WoodTrust Financial Corp grew its holdings in Eli Lilly and Company by 1.5% during the 3rd quarter. WoodTrust Financial Corp now owns 3,371 shares of the company’s stock valued at $3,901,000 after buying an additional 50 shares in the last quarter. Finally, Brown Shipley& Co Ltd grew its holdings in Eli Lilly and Company by 0.7% during the 3rd quarter. Brown Shipley& Co Ltd now owns 4,750 shares of the company’s stock valued at $5,496,000 after buying an additional 33 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 over the last ninety days. 0.14% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Price Performance
LLY stock opened at $1,177.57 on Friday. Eli Lilly and Company has a 52 week low of $783.85 and a 52 week high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a fifty day simple moving average of $1,174.35 and a two-hundred day simple moving average of $1,097.02. The firm has a market capitalization of $1.11 trillion, a P/E ratio of 39.52, a price-to-earnings-growth ratio of 1.44 and a beta of 0.46.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. During the same period in the prior year, the company earned $6.31 EPS. The business’s revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts anticipate that Eli Lilly and Company will post 36.64 earnings per share for the current fiscal year.
Key Stories Impacting Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: New Phase 3b TOGETHER-PsO data showed that combining Taltz with Zepbound produced broader biological effects than Taltz alone in adults with psoriasis and obesity. By Week 36, the combination changed 482 proteins versus 140 with Taltz alone and affected 467 genes versus 16, alongside improved skin clearance and weight loss. The findings could strengthen Lilly’s case for treating interconnected metabolic and inflammatory conditions. New Phase 3b data on Lilly’s Taltz and Zepbound
- Positive Sentiment: Analyst Cantor Fitzgerald raised its Eli Lilly price target to $1,440 from $1,410 and maintained an Overweight rating, implying meaningful upside based on continued obesity-drug demand and pipeline execution. Cantor Fitzgerald raises pharma price targets
- Positive Sentiment: Recent coverage continues to highlight strong Zepbound demand, potential retatrutide and Foundayo catalysts, and expansion in oncology and Alzheimer’s research. Lilly’s second-quarter revenue growth of roughly 48% and raised outlook provide fundamental support for the long-term growth narrative.
- Neutral Sentiment: Despite its growth profile, Lilly trades below its historical average forward earnings multiple. That may indicate a valuation opportunity, but it also reflects investor concerns about competition, pricing pressure and whether the company’s exceptional growth can continue.
- Neutral Sentiment: Lilly and Nvidia reportedly plan to commit up to $1 billion to an artificial-intelligence drug-discovery laboratory. The initiative may improve future research productivity, although it is unlikely to materially affect near-term earnings. Nvidia and Eli Lilly AI drug-discovery lab
- Negative Sentiment: Lilly’s largest shareholder filed to sell approximately $347 million of stock. The transaction may be routine portfolio management, but its size can raise concerns about insider or major-holder confidence and create additional supply.
- Negative Sentiment: The company is facing a lawsuit from a patient alleging stomach problems linked to Mounjaro and Trulicity. Litigation creates regulatory, legal and reputational risk, although the financial impact remains uncertain.
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.
Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
